Key result
A hybrid approach of percutaneous mitral valve repair followed by MIDCAB successfully treated a 76-year-old high-risk patient, who remained stable without recurrent symptoms at 2 years.
Why the study?
Is a hybrid approach of percutaneous mitral valve repair followed by MIDCAB effective for severe ischemic mitral valve regurgitation and coronary artery disease in a high-risk patient?
Case Report (n=1)
Is a hybrid approach of percutaneous mitral valve repair followed by MIDCAB effective for severe ischemic mitral valve regurgitation and coronary artery disease in a high-risk patient?
A hybrid approach of MitraClip followed by MIDCAB may be an effective minimally invasive treatment for high-risk patients with severe ischemic mitral valve regurgitation and coronary artery disease.
Hybrid MitraClip-then-MIDCAB may be feasible yet risks complications in high-risk ischemic MR; leaves open need for prospective safety data.
BACKGROUND: We present a 76-year-old poly-morbid male patient suffering from severe ischemic mitral valve regurgitation. A hybrid approach was suggested by the heart team to treat his multifaceted cardiac pathologies. METHODS: At first percutaneous mitral valve repair with the mitraclip device was performed to reduce surgical risk. This was then followed by minimally invasive direct coronary artery bypass (MIDCAB). RESULTS: At day 20 Post mitraclip intervention the patient suffered gastrointestinal bleeding which needed argon plasma coagulation (APC)-therapy and multiple blood transfusions. Stage II of the hybrid procedure was executed on post-intervention day 34 by minimally invasive direct coronary artery bypass (MIDCAB) to left anterior descending artery (LAD). Seven days later the patient was discharged. Up to two years of follow-up, the patient is in stable condition, without recurrent cardiac symptoms. CONCLUSION: Hybrid approach of percutaneous mitral valve repair followed by MIDCAB is an effective minimally invasive treatment for severe ischemic mitral valve regurgitation and coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Öner et al. (2021) conducted a case report in Severe ischemic mitral valve regurgitation and coronary artery disease (n=1). Hybrid approach of percutaneous mitral valve repair (MitraClip) followed by MIDCAB was evaluated on Clinical status and recurrent cardiac symptoms. A hybrid approach of percutaneous mitral valve repair followed by MIDCAB successfully treated a 76-year-old high-risk patient, who remained stable without recurrent symptoms at 2 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: